Close Menu

NEW YORK (GenomeWeb) — Startup Cadex Genomics expects to soon launch a laboratory-developed test that uses a real-time quantitative PCR liquid biopsy assay with retrotransposon-based quantification technology to analyze the variable length of DNA fragments from cancer cells and provide clinicians with a tool to evaluate how cancer patients diagnosed with stage IV solid tumors are responding initially to treatment. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.